Abstract: A calf stretching apparatus having a base having a lower surface defining a lower surface plane, a front end, a rear end opposing the rear end of the base, the rear end of the base having a rear edge defining a recessed base through opening and a foot placement platform with a front end, a rear end opposing the front end of the foot placement platform, a platform surface spanning in an upward direction with respect the base from the front end of the foot placement platform to the rear end of the foot placement platform and disposed at an acute angle with respect to the lower surface plane, a platform sidewall surrounding the platform surface on three sides thereof, wherein the rear end of the foot placement platform has a rear edge defining a recessed platform through opening aligned with the recessed base through opening.

Abstract: A device for correcting foot alignment is provided. The device includes a base configured to receive at least a portion of a person's foot and an elongate alignment member extending from the lateral side of the base. The elongate alignment member comprises a bracket and a stopper extending outwardly from the bracket. The alignment member prevents the person's foot from rotating outwardly when the person is wearing the device.

Abstract: A portable rehab station, including left and right outriggers, each having a forward end and a rearward end, the left and right outriggers being pivotally connected at the bottom ends of the respective left and right frame members to pivot between retracted and expanded positions, the retracted position including the left and right outriggers being generally mutually parallel, and the expanded position including the left and right outriggers being spread out at an angle of between about six and ten degrees relative to each other; a front, ground-engageable caster connected to the forward end of each of the left and right outriggers and a rear, ground-engageable caster connected to the rearward end of each of the left and right outriggers; and an actuator assembly connected with the frame and operably connected with the left and right outriggers to selectively pivot the left and right outriggers between the retracted and expanded positions.

Abstract: A beauty instrument capable of imparting a massaging effect to skin. A beauty instrument is configured such that a pair of balls is supported at the tip of a handle. The balls are positioned at a distance from each another, and are capable of rotating around respective axes thereof.

Abstract: Adult devices for sexual and therapeutic purposes are typically developed and marketed into a limited number of developed countries with high disposable incomes. However, these represent a fraction of the total potential adult population and accordingly it would be beneficial in all of these markets to offer low cost, ideally very low cost, but effective devices. Solutions meeting this very low cost manufacturing requirement as well as offering new concepts such as limited use or disposable devices are presented exploiting blow molding techniques. Further, many potential markets present issues not prevalent in historical markets that may make it difficult for individuals to acquire devices, even without the financial issues, and hence solutions are presented wherein adult devices can be acquired and/or marketed in manners that address or mitigate these issues.

Abstract: A portable vibration device for soothing an infant. The portable vibration device includes a vibration pad portion, a control pad connected and a neck portion. The neck portion extends between the vibration pad and the control pad. A vibration circuit is provided to control a vibration element in the vibration pad. The circuit electrically connects the control pad to the vibration pad. A cushion is provided around the vibration pad portion and a cover is disposed around the cushion and the internal components of the vibration device.

Abstract: A child-resistant package is provided having a hollow carton with opposed front and rear walls and a separate blister card having a plurality of separate, spaced-apart hollow blister compartments contained therein. The front wall of the hollow carton comprising a structure including an exterior wall panel having a plurality of openings, gates, or pull tabs and an interior wall panel adhesively secured to the exterior wall panel. The interior wall panel of the front wall has a plurality of chads aligned between the openings and blister compartments. The rear wall of the hollow carton comprising a structure including an exterior wall panel having a plurality of separate, openings and an interior wall panel adhesively secured to the exterior wall panel. The interior wall panel of the rear wall having a plurality of break-away chads located directly between the blister compartments and the openings.

Abstract: A packaging system is provided for securely and irreversibly holding a sterile product. The packaging system includes a primary packaging holder and a secondary packaging holder. The secondary packaging holder has a body made up of a top having a receiving portion configured to receive the primary packaging holder, a base having a plurality of apertures and a first and second planar wall extending from opposing ends of the base in parallel to opposing ends of the top. The secondary packaging holder also has a first and second plate configured to secure opposing ends of an opening though the body. The first plate comprises a first securing feature, and the second plate comprises a second securing feature. The first and second securing features are capable of jointly securing and irreversibly holding the primary packaging holder in the secondary packaging holder.

Abstract: A medical connector system including a first connector and a second connector. The first connector has a housing, a biasing member, and at least one projection. The second connector has at least one groove for receiving the at least one projection. The proximal end of the second connector is configured to be at least partially disposed within the distal end of the housing of the first connector. Upon application and release of a first set of opposing axial forces applied to the connector system, the first connector is locked to the second connector and, upon application and release of a second set of opposing axial forces, the first connector is released from the second connector. The connectors may include indicators to show when the connector system is in the locked position.

Abstract: An adapter assembly for establishing bidirectional fluid connection between a cartridge and a vial includes a housing having an open first end adapted to engage the cartridge and a second open end adapted to engage the vial. The adapter includes a needle assembly having a first tip and a second tip, with the needle assembly disposed within the housing and at least partially supported by a needle holder. The needle assembly is movable relative to the housing from an initial position in which the first and second tip are isolated from the cartridge and vial, to an end of use position, in which first tip is engaged with the vial and the second tip is engaged with the cartridge, establishing fluid communication therebetween. The needle assembly is maintained in the initial position by a locking structure which is released by rotationally advancing the needle holder relative to the housing.

Abstract: A feeding assembly includes a container having an open top and defining a liquid chamber therein for holding a liquid. A collar assembly defines a closure for the open top of the container upon assembly with the container. A vent assembly is positionable at least in part on the open top of the container and is configured to facilitate venting of the container to atmosphere as liquid exits the feeding assembly during feeding. The vent assembly being disposed intermediate the container and the nipple, has at least one opening through which liquid is able to flow from the container to the nipple during feeding. The vent assembly has a siphon member extending longitudinally of the feeding assembly and generally away from the nipple and is configured to facilitate the flow of liquid from the nipple back into the container when feeding is ceased and the container is oriented generally upright.

Abstract: A pacifier system is configured for administering fluid to an infant. The system includes a pacifier having a supple nipple, a mouth guard, and a syringe coupler configured to removably attach to a syringe. A passageway extends through the pacifier and attaches to a standard oral syringe for expelling fluid from the syringe into the passageway of pacifier and into a mouth of an infant.

Abstract: A primer composition for a resin cured material according to the present disclosure comprising (A) a polymerizable monomer having a solubility parameter (an SP value) in the range of from 7.0 to 10.0, (B) a volatile organic solvent, (C) a polymerization catalyst and/or a polymerization accelerator, and (D) a polymerizable monomer having at least two polymerizable group.

Abstract: Aluminum chlorohydrate salts having an amount of Peak 1 material relative based on a total of Peaks 3, 4, and 5 of at least 20% as measured by size exclusion chromatography, together with water treatment compositions, antiperspirant compositions, and oral care compositions, comprising the same, and methods for making and using the same.

Abstract: A finisher composition in the form of an oil-in-water emulsion. The continuous aqueous phase of the emulsion is from about 20 to 85 wt % of water. The dispersed oil phase of the emulsion includes a non-volatile oil, which is at least 50% by weight of a liquid UV agent. The composition also includes from about 10 to 25 wt % of substantially spherical starch particles, silicone elastomer particles, or a combination of these. The particles have a particle size of from about 2 to 40 microns. The weight ratio of the non-volatile oil to the particles is from about 1:10 to about 1:1. The composition is substantially free of glycerin and, optionally, includes from about 1 to 20 wt % of a volatile oil.

Abstract: Biguanide-preserved precipitated calcium carbonate oral care compositions and methods of manufacture thereof are disclosed.

Abstract: The present disclosure relates to compositions containing a natural extract(s) and their fraction(s) and the use of such compositions for treatment of skin, hair and nail. For example, the present disclosure relates to compositions containing an aqueous extract of (i) Yacon leave, (ii) Amor Seco leave, or (iii) Porphyridium biomass, or a combination thereof and a pharmaceutically or cosmetically acceptable carrier use on hair skin and nails for cosmetic purposes.

Abstract: A supplement composition formulated to support the health of a human's hair skin and nails containing biotin, Haematococcus pluvialis algae, and Reishi.

Abstract: The present invention provides a cationic arabinoxylan and the hydrophobically modified product thereof. The cationic arabinoxylan is prepared based on a cereal arabinoxylan and a quaternizing agent, with water as solvent and strong alkali as catalyst. The hydrophobically modified product is prepared based on cationic arabinoxylan and alkyl halide, with pyridine as catalyst. Said cationic arabinoxylan and the hydrophobically modified product thereof can be used as a conditioning agent or thickener in cosmetics or personal care compositions, and can also be used in textile, papermaking, pharmaceutical and food industry applications.

Abstract: Oral care compositions comprising have improved stability due to the removal of stannous ions and the inclusion of low molecular weight polyethylene glycols (PEGs). Compositions containing a source of zinc ions and PEG having a weight average molecular weight of 300 Da to 8000 Da and used for treating the oral cavity comprising administering to the oral cavity an oral care composition according to the present invention.

Abstract: Oral compositions containing a polyorganosilsesquioxane particle, preferably polymethylsilsesquioxane particles, an oxidizing agent and an orally-acceptable carrier. Method of using such compositions for the cleaning and polishing of dental enamel, such methods including the step of applying such oral care compositions to the teeth of a user.

Abstract: The invention relates to nail compositions comprising at least one silicone-organic polymer hybrid compound.

Abstract: An alcoholic extract of aerial parts of Solidago virgaurea subsp. alpestris, the method of production thereof, a cosmetic or dermatological composition containing it, as well as cosmetic and dermatological uses thereof, notably in the treatment of signs of skin ageing.

Abstract: The present invention relates generally to methods and compositions useful to cleanse, exfoliate, smooth, moisturize, hydrate, and/or improve the appearance and/or condition of skin and/or hair using a composition including shea butter, PEG-50 shea butter, and/or hydrated silica.

Abstract: Disclosed is a lipophilic extract of brown algae gametophytes obtained by the method including the following consecutive steps: —a Step A) for preparing a hydro-alcoholic suspension of gametophyte cells by mixing an aqueous suspension of brown algae gametophyte cells with at least one aliphatic alcohol including 1 to 4 carbon atoms; —a Step B) for mixing the hydro-alcoholic suspension of algae gametophyte cells, obtained in Step A), with at least one triglyceride from fatty acids that include 8 to 22 carbon atoms; —a Step C) for adding water to the multiphase mixture obtained in Step B); and —a Step D) for isolating the lipophilic extract of brown algae gametophytes from the mixture obtained in Step C). Also disclosed are the cosmetic and pharmaceutical use of the extract.

Abstract: The present invention provides a topical composition comprising (a) 0.5 to 25 weight percent of glycerin; (b) 0.1 to 5 weight percent of cetearyl olivate; (c) 0.1 to 5 weight percent of sorbitan olivate; and (d) 0.01. to 1 weight percent of extract of Pichia anomala; wherein the composition is substantially free of fatty alcohols and is in the form of a gel cream.

Abstract: Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X-rays and/or scintillation. Optionally, the photo sensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise inorganic nanoparticles in the cavities or channels of the MOF or can be used in combination with an inorganic nanoparticle. Also described are methods of using MOFs and/or inorganic nanoparticles in photodynamic therapy or in X-ray induced photodynamic therapy, either with or without the co-administration of one or more immunotherapeutic agent and/or one or more chemotherapeutic agent.

Abstract: A method of treating a patient in need of therapy with fentanyl or a salt thereof, the method comprising providing a ready-to-administer solution consisting essentially of fentanyl or a salt thereof as the sole active ingredient, a sugar or sugar alcohol and water for injection, the solution having a pH in the range of 3.5 to 7.5, and parenterally administering the solution to the patient.

Abstract: Methods of making a dry powder, comprise (a) delivering a liquid solution or suspension and a second, immiscible fluid to a flow path, (b) transporting the liquid solution or suspension and the immiscible fluid along the flow path, wherein the flow path includes two or more flow passages of different diameters, at least one flow divider which divides and diverts the flowing mixture into at least two separate passages, wherein the separate passages subsequently intersect to combine their respective flows into a single flowing stream, (c) rapidly reducing the pressure of the single flowing stream, whereby droplets are formed, and (d) passing the droplets through a flow of inert drying gas to form a dry powder. A nebulizing nozzle includes an inlet, a flow path as described, and a restrictor nozzle outlet.

Abstract: The present invention provides a solid dispersion of rufinamide in combination with a pharmaceutically acceptable carrier, process for its preparation and pharmaceutical compositions comprising it.

Abstract: A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system. A method of treating cancer by administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system to a subject in need of treatment, and treating cancer. A method of overcoming multidrug resistance by exposing a multidrug resistant cell to an effective amount of a pharmaceutical composition including an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system, and inducing the death of the multidrug resistant cell. A method of eliminating a cancer stem cell. Methods of reducing stemness of a cancer stem cell, retaining drug in the body, and providing a slower release profile.

Abstract: The invention provides extended release pro-liposomal, non-aqueous, pharmaceutical formulations of a local anesthetic in the form of a clear oily solution and methods for making same. The formulations can be administered by infiltration into an incision, or by injection.

Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

Abstract: The present invention provides lyophilized formulations of active agents, particularly of TAT-NR2B9c including histidine, trehalose and lysine. TAT-NR2B9c has shown promise for treating stroke, aneurysm, subarachnoid hemorrhage and other neurological or neurotraumatic conditions. Such formulations are stable at ambient temperature thus facilitating maintenance of supplies of such a formulation in ambulances for administration at the scene of illness or accident or in transit to a hospital.

Abstract: The invention relates to solid medicinal forms containing at least one active ingredient and at least one pharmaceutically compatible, water soluble drying agent which is selected from the group consisting of trimagnesium dicitrate and/or calcium chloride, the solid medicinal form having a drying loss of at most 6% and a relative equilibrium moisture content of 25% or less. The invention also relates to solid medicinal forms containing a moisture-sensitive active ingredient and trimagnesium dicitrate.

Abstract: A solid dispersion comprising suvorexant or a salt thereof in amorphous form and at least one pharmaceutically acceptable matrix compound, wherein the matrix compound is (i) a polymer and wherein the solid dispersion contains the suvorexant or salt thereof in an 5 amount of at least 50 weight-% based on the combined weight of the suvorexant or salt thereof and the at least one matrix compound, or (ii) a silicon-based inorganic adsorbent.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: Compositions of the present invention, comprising at least one digestive enzyme (e.g., pancrelipase) are useful for treating or preventing disorders associated with digestive enzyme deficiencies. The compositions of the present invention can comprise a plurality of coated particles, each of which is comprised of a core coated with an enteric coating comprising at least one enteric polymer and 4-10% of at least one alkalinizing agent, or have moisture contents of about 3% or less, water activities of about 0.6 or less, or exhibit a loss of activity of no more than about 15% after six months of accelerated stability testing.

Abstract: Abuse-resistant oral dosage forms suitable for administration of pharmacologically active agents are provided.

Abstract: The present invention relates to microcapsules and to methods for them. The microcapsules comprise a polymeric coating that is at least partly crosslinked with a polymeric matrix comprising a polysaccharide. In the matrix, a lipid and an active agent or a prodrug or salt thereof are embedded, the lipid preferably having a melting point of at least 30° C. The microcapsules can be used as a medicament, dietary supplement or food additive, the microcapsules comprising a polymeric coating that is at least partly crosslinked with a polymeric matrix comprising a polysaccharide. As above, a lipid and an active agent or a prodrug or salt thereof are embedded in the matrix, with the lipid preferably having a melting point of at least 30° C. Methods for treating diarrhea or preventing colon cancer comprising administering such microcapsules are also disclosed.

Abstract: Provided herein are methods of inhibiting proliferation of one or more tumor cells comprising contacting the one or more tumor cells with a composition comprising one or more epigenetic drugs that inhibit one or more epigenetic mechanisms of the tumor cells, wherein the one or more epigenetic drugs are encapsulated in a nanogel. The invention is also directed to methods of treating a tumor, metastasis of a tumor or a combination thereof in an individual in need thereof. The invention is also directed to a method of sequentially delivering one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell and one or more chemotherapeutic drugs to an individual that has a tumor. Compositions which comprise one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell, wherein the one or more epigenetic drugs are encapsulated in a nanogel.

Abstract: The present invention refers to lipid nanoparticles comprising a growth factor and/or an antimicrobial peptide and to the method for their preparation. Moreover, it refers to pharmaceutical compositions comprising such lipid nanoparticles, and a pharmaceutical acceptable carrier. Finally, it also refers to said pharmaceutical composition for its use as medicament and for its use in promoting wound healing, particularly by topical administration.

Abstract: The present invention provides prion-free compositions comprising nanoparticles comprising albumin and substantially water insoluble drugs. Also provided are methods of making prion-free compositions and methods of removing prion proteins from the nanoparticle compositions. Methods of using the compositions, as well as kits useful for carrying out the methods are also provided.

Abstract: A cannabis based therapeutic product for treatment of chronic pain produced by separating hash resin from plant material of the cannabis plant, pressing the hash resin to expel oil, leaving spent hash resin, extracting further cannabinoids from the spent hash resin using MCT oil, separating the cannabis compounds from the oils using high pressure liquid chromatography, flash chromatography, or similar techniques, and processing selected cannabis compound formulations into a pill, tablet, liquid, or other form suitable for administration as a therapeutic product for treatment of chronic pain, optionally with the further step of enriching the product with a formulation comprising at least 1% by weight purified -myrcene, prior to processing into a final product.

Abstract: A composition for the treatment of emesis comprising 8-hydroxy-2-(dipropylamino)tetralin in which the ratio of the S enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin to the R enantiomer of the 8-hydroxy-2-(dipropylamino)tetralin is between 2:1 and 10:1, and a method of treating or preventing emesis with such a composition.

Abstract: A composition of matter comprising in combination as component (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol compound, and as component (b) at least one antiepileptic, a pharmaceutical formulation and a dosage form comprising said composition of matter, and a method of treating pain, e.g. neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, whereby component (a) may be administered before or after component (b) and whereby components (a) or (b) are administered to the mammal either via the same or a different pathway of administration.

Abstract: Methods of treating and/or preventing a cardiovascular event in a patient, the method comprising orally administering a colchicine to a patient who is receiving concurrent treatment with at least one antiplatelet agent, thereby treating and/or preventing the cardiovascular event in the patient are provided.

Abstract: The present invention relates to TRPV1 selective agonist compositions including a capsaicinoid, a surfactant and an extended release agent, and to methods of manufacture and methods of providing pain relief as well as treating a variety of disorders with such compositions.

Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.

Abstract: The present invention provides methods for treating and/or preventing mucositis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.